{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:33:46Z","timestamp":1778740426382,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":281,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to assess the prevalence of Varicella-Zoster Virus (VZV) immunity, vaccination uptake and incidence of VZV-related events in inflammatory arthritis (IA) patients initiating biologic or targeted synthetic disease-modifying antirheumatic drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational study was conducted in a single hospital between March 2019 and December 2020. Ninety-three IA patients were included. Data were collected from electronic health records and analysed using the chi-squared test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The majority of patients (91.4%) were seropositive for VZV, reaffirming the necessity for vaccination. In total, 8.6% of the cohort received the Zostavax vaccine, despite a small yet significant number of patients (4.3%) experiencing Herpes Zoster after initiating treatment. Multiple factors contributed to low vaccine uptake, including limited vaccine availability, discrepancies between the British Society for Rheumatology and Joint Committee on Vaccination and Immunisation guidelines, vaccine hesitancy and concerns regarding vaccine efficacy and risks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Significant VZV immunity exists among patients prior to targeted therapy commencement. Risk factors for VZV-related events include Janus kinase inhibition, increasing age and long-term steroid use. VZV-related events occurred exclusively in patients with prior viral immunity. Despite most patients having serological evidence of prior VZV exposure, our study exposes critical gaps between current clinical guidelines and practice, particularly in VZV vaccine uptake. Barriers to vaccination include inconsistent guidelines, limited vaccine availability and patient-level hesitancy. This is concerning as our cohort demonstrated small but significant rates of zoster, mostly among patients on long-term steroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae127","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:28:18Z","timestamp":1728404898000},"source":"Crossref","is-referenced-by-count":3,"title":["The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-2758","authenticated-orcid":false,"given":"Saad","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Addenbrookes Hospital , Cambridge,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-8988","authenticated-orcid":false,"given":"Martin","family":"Lauran","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaeze","family":"Ugwoke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Addenbrookes Hospital , Cambridge,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Walton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Colchester Hospital , Essex,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Holroyd","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospital Southampton NHS Foundation Trust , Southampton,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2024102804454784900_rkae127-B1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"2024102804454784900_rkae127-B2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"2024102804454784900_rkae127-B3","first-page":"1723","article-title":"Evaluation and management of Herpes Zoster Ophthalmicus","volume":"66","author":"Shaikh","year":"2002","journal-title":"AFP"},{"key":"2024102804454784900_rkae127-B4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","article-title":"Immunosenescence: emerging challenges for an ageing population","volume":"120","author":"Aw","year":"2007","journal-title":"Immunology"},{"key":"2024102804454784900_rkae127-B5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/infdis\/172.3.706","article-title":"The epidemiology of varicella and its complications","volume":"172","author":"Choo","year":"1995","journal-title":"J Infect Dis"},{"key":"2024102804454784900_rkae127-B6","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for Herpes Zoster: A systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2024102804454784900_rkae127-B7","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"key":"2024102804454784900_rkae127-B8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024102804454784900_rkae127-B9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024102804454784900_rkae127-B10","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024102804454784900_rkae127-B11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"2024102804454784900_rkae127-B12","first-page":"406","article-title":"Shingrix: a new Herpes Zoster vaccine","volume":"44","author":"Maltz","year":"2019","journal-title":"Pharm Ther"},{"key":"2024102804454784900_rkae127-B13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the Live Zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"2024102804454784900_rkae127-B14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2024102804454784900_rkae127-B15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2024102804454784900_rkae127-B16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102804454784900_rkae127-B17","author":"GOV.UK [Internet]"},{"key":"2024102804454784900_rkae127-B18","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"2024102804454784900_rkae127-B19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3899\/jrheum.181376","article-title":"Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care","volume":"47","author":"Qendro","year":"2020","journal-title":"J Rheumatol"},{"key":"2024102804454784900_rkae127-B20","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arth Res Ther"},{"key":"2024102804454784900_rkae127-B21","first-page":"60","article-title":"Predictive value of a history of varicella infection","volume":"51","author":"Holmes","year":"2005","journal-title":"Can Fam Physician"},{"key":"2024102804454784900_rkae127-B22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024102804454784900_rkae127-B23","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1093\/rheumatology\/kead057","article-title":"Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys","volume":"62","author":"Sen","year":"2023","journal-title":"Rheumatology"},{"key":"2024102804454784900_rkae127-B24","doi-asserted-by":"crossref","first-page":"e43893","DOI":"10.2196\/43893","article-title":"Willingness to vaccinate against herpes zoster and its Associated factors across WHO regions: global systematic review and Meta-analysis","volume":"9","author":"Wang","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"2024102804454784900_rkae127-B25","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.vaccine.2021.04.062","article-title":"Older adults\u2019 vaccine hesitancy: psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake","volume":"39","author":"Nicholls","year":"2021","journal-title":"Vaccine"},{"key":"2024102804454784900_rkae127-B26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/1756-185X.13585","article-title":"Increased risk of opportunistic infection in early rheumatoid arthritis","volume":"22","author":"Kim","year":"2019","journal-title":"Int J Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae127\/59639783\/rkae127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/4\/rkae127\/60138167\/rkae127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/4\/rkae127\/60138167\/rkae127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:46:05Z","timestamp":1730090765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae127\/7815735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae127","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"rkae127"}}